A5026816972- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Chronic Lymphocytic Leukemia Research
- Hereditary Neurological Disorders
- Immunotherapy and Immune Responses
- SARS-CoV-2 and COVID-19 Research
- Systemic Sclerosis and Related Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Acute Lymphoblastic Leukemia research
- Glaucoma and retinal disorders
- Ocular Diseases and Behçet’s Syndrome
- Amyotrophic Lateral Sclerosis Research
- Sarcoidosis and Beryllium Toxicity Research
- RNA regulation and disease
- Neuroinflammation and Neurodegeneration Mechanisms
- Inflammatory Myopathies and Dermatomyositis
- Mast cells and histamine
- interferon and immune responses
- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Vasculitis and related conditions
- Immunodeficiency and Autoimmune Disorders
- CNS Lymphoma Diagnosis and Treatment
- Muscle and Compartmental Disorders
Heinrich Heine University Düsseldorf
2020-2025
Düsseldorf University Hospital
2021-2024
Essen University Hospital
2021-2023
The University of Sydney
2023
Justus-Liebig-Universität Gießen
2023
Palacký University Olomouc
2023
Medical University of Vienna
2023
University Hospital of Basel
2023
University of Basel
2023
University Hospital Münster
2019-2021
To analyze whether 1 of the 2 apheresis techniques, therapeutic plasma exchange (PE) or immunoadsorption (IA), is superior in treating neuromyelitis optica spectrum disorder (NMOSD) attacks and to identify predictive factors for complete remission (CR).This retrospective cohort study was based on registry German Neuromyelitis Optica Study Group, a nationwide network established 2008. It recruited patients with diagnosed according 2006 Wingerchuk criteria aquaporin-4...
Background Vaccination has proven to be effective in preventing SARS-CoV-2 transmission and severe disease courses. However, immunocompromised patients have not been included clinical trials real-world data point an attenuated immune response vaccines among with multiple sclerosis (MS) receiving immunomodulatory therapies. Methods We performed a retrospective study including 59 ocrelizumab (OCR)-treated MS who received vaccination. Anti-SARS-CoV-2-antibody titres, routine blood parameters...
Introduction: The efficacy of anti-CD20 antibodies has significantly contributed to advancing our understanding disease pathogenesis and improved treatment outcomes in relapsing-remitting multiple sclerosis (RRMS). A comprehensive analysis the peripheral immune cell profile, combined with prospective clinical characterization, RRMS patients treated ocrelizumab (OCR) or ofatumumab (OFA) was performed further understand reconstitution following B-cell depletion. Methods: REBELLION-MS is a...
To investigate if patients with neuromyelitis optica spectrum disorder (NMOSD) develop subclinical visual pathway impairment independent of acute attacks.A total 548 longitudinally assessed full-field evoked potentials (VEP) 167 NMOSD from 16 centers were retrospectively evaluated for changes P100 latencies and P100-N140 amplitudes. Rates change in (RCL) amplitudes (RCA) over time analyzed each individual eye using linear regression compared generalized estimating equation models.The rates...
Myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) is an inflammatory autoimmune condition of the central nervous system. However, data on pain and depression have remained scarce. The aim this study was to assess features chronic as well their impact health-related quality life (hr-QoL) in MOGAD.Patients with MOGAD were identified Neuromyelitis Optica Study Group registry. Data acquired by a questionnaire, including clinical, demographic, (PainDetect, Brief Pain...
Abstract Background Immune dysregulation is a hallmark of autoimmune diseases the central nervous system (CNS), characterized by an excessive immune response, and primary CNS tumors (pCNS-tumors) showing highly immunosuppressive parenchymal microenvironment. Methods Aiming to provide novel insights into pathogenesis autoimmunity cerebral tumor immunity, we analyzed peripheral blood (PB) cerebrospinal fluid (CSF) 81 limbic encephalitis (ALE), 148 relapsing–remitting multiple sclerosis (RRMS),...
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment cladribine.We evaluated our prospective bicentric cladribine cohort. Cladribine-treated a skin AE were identified.Two hundred thirty-nine cladribine-treated MS evaluated. Seventy-seven (32%) showed at least 1 median month after initiation (range: 1-12). Within first 3 months last exposition, hair thinning (n = 28, 12%), rash 20; 8%), mucositis 13, 5%), and pruritus 6, 3%)...
Background and Objectives Cladribine is a cytotoxic drug which ameliorates the clinical course of relapsing-remitting multiple sclerosis. In addition to cytotoxicity, mode action may include immunomodulatory mechanisms. This in vitro study was designed investigate cladribine's effects on cell function after removal cladribine distinguish versus effects. Methods Cells were incubated absence or presence (1×10-8 M 1×10-5 M) for 72 h. removed from culture surviving peripheral blood mononuclear...
Dalfampridine exerts beneficial effects on walking ability in a subgroup of patients with multiple sclerosis (MS). These are termed "responders". Here, we investigated whether the responder status respect to mobility measures would determine dalfampridine treatment effect other MS symptoms. We therefore assessed ability, upper limb function, cognition, fatigue, visual evoked potentials (VEPs), depression, and quality life before after treatment.Patients impaired were recruited. Maximal...
Therapeutic options targeting inflammation in multiple sclerosis (MS) have evolved rapidly for relapsing-remitting MS, whereas few therapies are available progressive forms of particular secondary MS (SPMS). The approval siponimod SPMS has allowed optimism the otherwise discouraging therapeutic landscape.We conducted a retrospective, multicenter, non-interventional study analyzing efficacy and safety under real-world conditions 227 patients. According to retrospective framework, data was...
Cyclic GMP-AMP-synthase is a sensor of endogenous nucleic acids, which subsequently elicits stimulator interferon genes (STING)-dependent type I (IFN) response defending us against viruses and other intracellular pathogens. This pathway can drive pathological inflammation, as documented for interferonopathies. In contrast, specific STING activation subsequent IFN-β release have shown beneficial effects on experimental autoimmune encephalomyelitis (EAE) model multiple sclerosis (MS). Although...
B cell-depleting antibodies were proven as effective strategy for the treatment of relapsing multiple sclerosis (RMS). The monoclonal antibody ocrelizumab was approved in 2017 United States and 2018 European Union, but despite efficacy randomized, controlled clinical trials, its effectiveness real-world setting remains to be fully elucidated. In particular, most study patients naive or switched from injectable therapies, whereas oral substances made up >1% previous treatments.We evaluated...
Cladribine has been approved for the treatment of multiple sclerosis (MS) and its administration results in a long-lasting depletion lymphocytes. As lymphopenia is known to hamper immune responses vaccination, we evaluated immunogenicity influenza vaccine patients undergoing cladribine at different stages vs. controls. The antibody response 90 cladribine-treated MS was prospectively compared with 10 control subjects receiving platform immunotherapy (NCT05019248). Serum samples were collected...
Relapse and MRI activity usually decline with aging but are replaced by progression independent of relapse (PIRA) in patients multiple sclerosis (PwMS). However, several older PwMS continue to experience clinical relapses, the impact on their disease remains undetermined. We aimed determine an index outcomes than 50 years identify risk factors disadvantageous outcomes.
A critical issue in the management of relapsing MS (RMS) is discontinuation disease-modifying treatments (DMT) due to lack efficacy, intolerability or impending risks. With new therapeutic agents introduced into treatment RMS, immediate- and long-term consequences sequential drug use, as well effect sequence which drugs are given, unclear but may affect adverse events, immunocompetence. In absence clinical studies specifically addressing these concerns, observations from practice particular...
Introduction Given the varying severity of coronavirus disease 2019 (COVID-19) and rapid spread Severe-Acute-Respiratory-Syndrome-Corona-Virus-2 (SARS-CoV-2), vaccine-mediated protection particularly vulnerable individuals has gained increasing attention during course pandemic. Methods We performed a 1-year follow-up study 51 ocrelizumab-treated patients with multiple sclerosis (OCR-pwMS) who received COVID-19 vaccination in 2021. retrospectively identified 37 additional OCR-pwMS, 42 pwMS...
For treatment of relapsing-remitting multiple sclerosis (RRMS), a broad range disease-modifying therapies (DMT) is available. However, few comparative effectiveness studies between different drugs have been performed.This study aimed to compare the efficacy and continuation natalizumab ocrelizumab in real-world cohort patients with (RRMS) from two German university hospitals.We performed retrospective analysis RRMS who initiated or January 2016 April 2019 at hospitals Mainz Düsseldorf....
To provide further evidence for sirolimus, a mammalian target of rapamycin inhibitor, as treatment strategy patients with inclusion body myositis (IBM).We acquired longitudinal clinical data and immunological assessments CD8+ T-cell subsets in peripheral blood evaluation potential anti-inflammatory effects sirolimus.Therapy sirolimus 2 mg/day by mouth led to rapid sustained improvement motor symptoms an observation period more than 1 year. Treatment was well tolerated, no occurrence adverse...
Abstract Background and purpose To provide an overview on the status of clinical research in neurology Germany. Methods German university hospitals, nonuniversity neurological medical practices were surveyed regarding their activities during period 2013 to 2017. Results Fifty percent 10.6% 5.2% Germany responded our questionnaire. More than 80% studies conducted have been phase III/IV noninterventional trials (NISs), whereas <1% I 3.5% investigator‐initiated (IITs). University hospitals...
Thursday, April 30April 14, 2020Free AccessCharacterization of T cells in NMOSD patients - an emerging role for disease pathogenesis (4017)Maren Lindner, Urvashi Bhatia, Andreas Schulte-Mecklenbeck, Timo Wirth, Catharina Gross, Tyge Schmidt, Melanie Korsen, … Show All , Tilman Schneider-Hohendorf, Nicholas Schwab, Sumanta Barman, Orhan Aktas, Norbert Goebels, Anne Winkler, Christine Stadelmann-Nessler, Wolfgang Brueck, Tania Kuempfel, Nadja Siebert, Friedemann Paul, Ingo Kleiter, Heinz...